Sreevalsa Appukkuttan, MPH

Director, Data Generation Observational Studies
Bayer US

Poster(s):

• (303) Real-world (RW) sequential regorafenib and trifluridine/tipiracil + bevacizumab (BEV) treatment for metastatic colorectal cancer (mCRC) in the United States (US) community oncology setting A post-hoc analysis of SEQRT2 study
  Wednesday, October 29, 2025

• (330) Budget impact of darolutamide + ADT for mCSPC from a United States payer perspective
  Wednesday, October 29, 2025